Pharma BD Deal Intelligence
Pfizer's $6.7B cash acquisition of Arena Pharmaceuticals paid off on thesis: etrasimod won FDA approval as VELSIPITY for ulcerative colitis in October 2023, with EU approval following in 2024. Pfizer has since pruned the broader program, dropping Phase 2 atopic dermatitis and alopecia areata studies in May 2024 to narrow focus onto the approved GI indication.
Pfizer acquired Arena Pharmaceuticals for $6.7B.
Pfizer completed its $6.7 billion acquisition of Arena Pharmaceuticals, gaining etrasimod, an oral selective S1P receptor modulator in development for…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer acquired Arena Pharmaceuticals for $6.7 billion in cash ($100.00/share) via a tender offer plus second-step merger, announced December 13, 2021 and completed March 11, 2022. The strategic rationale was Arena's immuno-inflammatory pipeline, led by etrasimod, an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator. Etrasimod won U.S. FDA approval as VELSIPITY for moderately-to-severely active ulcerative colitis on October 12, 2023, followed by EU approval in 2024 — validating the deal's core thesis. Pfizer subsequently pruned the broader etrasimod program, discontinuing Phase 2 studies in atopic dermatitis and alopecia areata in May 2024 as part of a cost-and-pipeline review, narrowing the asset toward its approved UC indication and adjacent GI development.
900K US cases/yr · $12.0B Global UC Market (2024)
Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon. The treatment landscape includes aminosalicylates, steroids, biologics (anti-TNF, anti-integrin, anti-IL-12/23), JAK inhibitors, and S1P modulators. Velsipity offers oral once-daily convenience as the second S1P modulator approved for UC.
Velsipity (etrasimod) FDA-approved October 2023. Phase 3 showed 27-32% remission vs 7% placebo. Competes with Zeposia (ozanimod) from BMS as well as JAK inhibitors Xeljanz and Rinvoq. Oral convenience differentiates from injectable biologics like Entyvio and Stelara.
Pfizer acquired Arena at $100/share for $6.7B to gain etrasimod S1P modulator for UC and other autoimmune conditions.
Etrasimod (Velsipity) approved for moderately to severely active UC in adults based on Phase III ELEVATE trials.
Pfizer dropped mid-stage Arena assets beyond etrasimod as part of portfolio cleanup.
European Commission approved Velsipity for UC in patients 16+, expanding global commercial footprint.
Approved but Early Commercial Phase. Assessment of Pfizer Inc.'s $6.7B acquisition of Arena Pharmaceuticals and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Arena Pharmaceuticals (this deal) | 2021 | $6.7B | 63 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2021 deals · Pfizer Inc. deals · Gastroenterology deals